Vietnam Investment Review

BiPASS Prostate Cancer Study Begins Patient Dosing

The phase three clinical trial reached a milestone with its first American participant receiving treatment, advancing ...
NOLA.com

Here are 6 stories that highlight progress from around the world

Discover inspiring stories of global progress in primary education, health advancements, conservation efforts and more.

Telix Pharmaceuticals Limited: First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...

Prostate cancer drug to be made available to thousands more patients

Life-extending prostate cancer drug to be made available to thousands more patients - Men with high-risk prostate cancer that ...

Thousands more men to be offered life-extending prostate cancer drug on NHS

NHS England has announced that men whose high-risk prostate cancer has not yet spread will be able to receive the drug, ...

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate ...

The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

Researchers uncover how E. coli bacteria sneak into the prostate

A research team at the University of Würzburg has, for the first time, uncovered how E. coli bacteria sneak into the prostate ...